Advertisement

Behçet Disease

  • Erdal Sag
  • Yelda Bilginer
  • Seza Ozen
Chapter
Part of the Rare Diseases of the Immune System book series (RDIS)

Abstract

Behçet disease (BD) is a multisystemic autoinflammatory disorder of unknown etiology. BD is most common along the historical Silk Road from Far East Asia to the Mediterranean region. The disease is characterized by recurrent oral/genital ulcers and ocular, gastrointestinal, musculoskeletal, and nervous system involvement. BD is also a unique vasculitis affecting both arteries and veins of all sizes.

There are several sets of classification criteria for BD; however, the International Study Group (ISG) diagnostic/classification criteria and the recently proposed pediatric BD (PEDBD) criteria are the most widely used. There are no specific guidelines for the management of pediatric BD; however, very recently, the new European League Against Rheumatism (EULAR) recommendations for adult BD have been proposed.

Keywords

Behçet Vasculitis Oral ulcer Genital ulcer Uveitis Sinus thrombosis 

References

  1. 1.
    Jennette JC, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRefGoogle Scholar
  2. 2.
    Behcet H. Über rezidivierende, aphtöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr. 1937;105:1152–63.Google Scholar
  3. 3.
    Feigenbaum A. Description of Behcet’s syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40(6):355–7.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    International Study Group for Behcet’s Disease. Criteria for diagnosis of Behcet’s disease. Lancet. 1990;335(8697):1078–80.Google Scholar
  5. 5.
    Kone-Paut I, et al. Consensus classification criteria for paediatric Behcet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis. 2016;75(6):958–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Batu ED, et al. The performance of different classification criteria in paediatric Behcet’s disease. Clin Exp Rheumatol. 2017;35 Suppl 108(6):119–23.PubMedGoogle Scholar
  7. 7.
    Davatchi F, et al. Behcet’s disease in Iran: analysis of 6500 cases. Int J Rheum Dis. 2010;13(4):367–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Davatchi F, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57–65.PubMedCrossRefGoogle Scholar
  9. 9.
    Mahr A, et al. Population-based prevalence study of Behcet’s disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum. 2008;58(12):3951–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Hatemi G, Yazici Y, Yazici H. Behcet’s syndrome. Rheum Dis Clin North Am. 2013;39(2):245–61.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Leccese P, Yazici Y, Olivieri I. Behcet’s syndrome in nonendemic regions. Curr Opin Rheumatol. 2017;29(1):12–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Ozen S, et al. Childhood vasculitides in Turkey: a nationwide survey. Clin Rheumatol. 2007;26(2):196–200.PubMedGoogle Scholar
  13. 13.
    Kone-Paut I, et al. Familial aggregation in Behcet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135(1):89–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Gul A, et al. Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis. 2000;59(8):622–5.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Barnes CG, Yazici H. Behcet’s syndrome. Rheumatology (Oxford). 1999;38(12):1171–4.CrossRefGoogle Scholar
  16. 16.
    Remmers EF, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet’s disease. Nat Genet. 2010;42(8):698–702.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Morton LT, Situnayake D, Wallace GR. Genetics of Behcet’s disease. Curr Opin Rheumatol. 2016;28(1):39–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakano H, et al. GWAS-identified CCR1 and IL10 loci contribute to M1 macrophage-predominant inflammation in Behcet’s disease. Arthritis Res Ther. 2018;20(1):124.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Mizuki N, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Kirino Y, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A. 2013;110(20):8134–9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Hughes T, et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behcet’s disease. Arthritis Rheumatol. 2014;66(6):1648–58.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Coit P, Direskeneli H, Sawalha AH. An update on the role of epigenetics in systemic vasculitis. Curr Opin Rheumatol. 2018;30(1):4–15.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kirino Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behcet’s disease and epistasis between HLA-B∗51 and ERAP1. Nat Genet. 2013;45(2):202–7.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Takeuchi M, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behcet’s disease in HLA-B∗51 carriers. Ann Rheum Dis. 2016;75(12):2208–11.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Evans DM, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet. 2011;43(8):761–7.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Genetic Analysis of Psoriasis Consortium, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985–90.CrossRefGoogle Scholar
  27. 27.
    Hatemi G, et al. One year in review 2017: Behcet’s syndrome. Clin Exp Rheumatol. 2017;35 Suppl 108(6):3–15.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Deniz R, et al. Th17-inducing conditions lead to in vitro activation of both Th17 and Th1 responses in Behcet’s disease. Immunol Investig. 2017;46(5):518–25.CrossRefGoogle Scholar
  29. 29.
    Yazici H, et al. Behcet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107–19.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Seoudi N, et al. The oral mucosal and salivary microbial community of Behcet’s syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015;7:27150.PubMedCrossRefGoogle Scholar
  31. 31.
    Shimizu J, et al. Bifidobacteria abundance-featured gut microbiota compositional change in patients with Behcet’s disease. PLoS One. 2016;11(4):e0153746.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Zhou Q, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67–73.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Yazici H, Ugurlu S, Seyahi E. Behcet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43(3):275–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Kim DK, et al. Clinical analysis of 40 cases of childhood-onset Behcet’s disease. Pediatr Dermatol. 1994;11(2):95–101.PubMedCrossRefGoogle Scholar
  35. 35.
    Seyahi E, et al. Fever in Behcet’s syndrome. Clin Exp Rheumatol. 2013;31(3 Suppl 77):64–7.PubMedGoogle Scholar
  36. 36.
    International Team for the Revision of the International Criteria for Behcet’s Disease. The international criteria for Behcet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.CrossRefGoogle Scholar
  37. 37.
    Sakane T, et al. Behcet’s disease. N Engl J Med. 1999;341(17):1284–91.PubMedCrossRefGoogle Scholar
  38. 38.
    Kone-Paut I, et al. Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet’s disease: an international cohort study of 110 patients. One-year follow-up data. Rheumatology (Oxford). 2011;50(1):184–8.CrossRefGoogle Scholar
  39. 39.
    Atmaca L, et al. Behcet disease in children. Ocul Immunol Inflamm. 2011;19(2):103–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Reiff A, Kadayifcilar S, Ozen S. Rheumatic inflammatory eye diseases of childhood. Rheum Dis Clin North Am. 2013;39(4):801–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Sungur GK, et al. Clinical and demographic evaluation of Behcet disease among different paediatric age groups. Br J Ophthalmol. 2009;93(1):83–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Kone-Paut I. Behcet’s disease in children, an overview. Pediatr Rheumatol Online J. 2016;14(1):10.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Tugal-Tutkun I, et al. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Gallizzi R, et al. A national cohort study on pediatric Behcet’s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J. 2017;15(1):84.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Krupa B, et al. Pediatric Behcet’s disease and thromboses. J Rheumatol. 2011;38(2):387–90.PubMedCrossRefGoogle Scholar
  46. 46.
    Nanthapisal S, et al. Paediatric Behcet’s disease: a UK tertiary centre experience. Clin Rheumatol. 2016;35(10):2509–16.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kone-Paut I, et al. Clinical features of Behcet’s disease in children: an international collaborative study of 86 cases. J Pediatr. 1998;132(4):721–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Vivante A, et al. Intracardiac thrombus and pulmonary aneurysms in an adolescent with Behcet disease. Rheumatol Int. 2009;29(5):575–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Ozdal PC, et al. Central retinal artery occlusion associated with ocular Behcet’s disease. Eur J Ophthalmol. 2002;12(4):328–30.PubMedCrossRefGoogle Scholar
  50. 50.
    Willerding G, et al. Acute central retinal artery occlusion in Adamantiades-Behcet disease. Eye (Lond). 2007;21(7):1006–7.CrossRefGoogle Scholar
  51. 51.
    Esatoglu SN, et al. Bronchial artery enlargement may be the cause of recurrent haemoptysis in Behcet’s syndrome patients with pulmonary artery involvement during follow-up. Clin Exp Rheumatol. 2016;34(6 Suppl 102):92–6.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Seyahi E, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35–48.CrossRefGoogle Scholar
  53. 53.
    Melikoglu M, et al. The unique features of vasculitis in Behcet’s syndrome. Clin Rev Allergy Immunol. 2008;35(1–2):40–6.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Kural-Seyahi E, et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60–76.CrossRefGoogle Scholar
  55. 55.
    Siva A, Saip S. The spectrum of nervous system involvement in Behcet’s syndrome and its differential diagnosis. J Neurol. 2009;256(4):513–29.PubMedCrossRefGoogle Scholar
  56. 56.
    Al-Araji A, Kidd DP. Neuro-Behcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8(2):192–204.PubMedCrossRefGoogle Scholar
  57. 57.
    Akman-Demir G, Saip S, Siva A. Behcet’s disease. Curr Treat Options Neurol. 2011;13(3):290–310.PubMedCrossRefGoogle Scholar
  58. 58.
    Ogose T, et al. A case of recurrent myositis as the main manifestation of Behcet disease. Pediatr Int. 2010;52(2):e101–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Hatemi I, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016;95(16):e3348.CrossRefGoogle Scholar
  60. 60.
    Ozen S. The “other” vasculitis syndromes and kidney involvement. Pediatr Nephrol. 2010;25(9):1633–9.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Desbois AC, et al. Cardiovascular involvement in Behcet’s diseaseRev Med Interne. 2014;35(2):103–11.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Demirelli S, et al. Cardiac manifestations in Behcet’s disease. Intractable Rare Dis Res. 2015;4(2):70–5.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Ozluk E, et al. Histopathologic study of pathergy test in Behcet’s disease. Indian J Dermatol. 2014;59(6):630.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Yurdakul S, et al. The arthritis of Behcet’s disease: a prospective study. Ann Rheum Dis. 1983;42(5):505–15.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Ahn JK, et al. A comparative metabolomic evaluation of Behcet’s disease with arthritis and seronegative arthritis using synovial fluid. PLoS One. 2015;10(8):e0135856.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Maldini C, et al. Relationships of HLA-B51 or B5 genotype with Behcet’s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887–900.CrossRefGoogle Scholar
  67. 67.
    de Menthon M, et al. HLA-B51/B5 and the risk of Behcet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Hatemi G, et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808–18.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Yazici H, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322(5):281–5.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Hamuryudan V, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(6):443–50.PubMedCrossRefGoogle Scholar
  71. 71.
    Melikoglu M, et al. Short-term trial of etanercept in Behcet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98–105.PubMedGoogle Scholar
  72. 72.
    Alpsoy E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138(4):467–71.PubMedCrossRefGoogle Scholar
  73. 73.
    Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29(5):267–79.PubMedCrossRefGoogle Scholar
  74. 74.
    Hatemi G, et al. Apremilast for Behcet’s syndrome—a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Emmi G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Mirouse A, et al. Ustekinumab for Behcet’s disease. J Autoimmun. 2017;82:41–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Dick AD, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–87.CrossRefGoogle Scholar
  78. 78.
    Cantarini L, et al. Paradoxical mucocutaneous flare in a case of Behcet’s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141–3.PubMedCrossRefGoogle Scholar
  79. 79.
    Tugal-Tutkun I, et al. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–33.PubMedCrossRefGoogle Scholar
  80. 80.
    Atienza-Mateo B, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856–64.CrossRefGoogle Scholar
  81. 81.
    Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of Behcet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2017;26(7):1005–14.PubMedCrossRefGoogle Scholar
  82. 82.
    Seyahi E, Yazici H. To anticoagulate or not to anticoagulate vascular thrombosis in Behcet’s syndrome: an enduring question. Clin Exp Rheumatol. 2016;34(1 Suppl 95):S3–4.PubMedGoogle Scholar
  83. 83.
    Soysal T, et al. Bone marrow transplantation for Behcet’s disease: a case report and systematic review of the literature. Rheumatology (Oxford). 2014;53(6):1136–41.CrossRefGoogle Scholar
  84. 84.
    Noel N, et al. Long-term outcome of neuro-Behcet’s disease. Arthritis Rheumatol. 2014;66(5):1306–14.PubMedCrossRefGoogle Scholar
  85. 85.
    Saadoun D, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine (Baltimore). 2012;91(1):18–24.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Erdal Sag
    • 1
  • Yelda Bilginer
    • 1
  • Seza Ozen
    • 1
  1. 1.Department of Pediatric RheumatologyHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations